Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.

Cancer Recurrence, Clinical Trials, High Risk Prostate Cancer, Metastatic Castration Resistant Prostate Cancer (MCRPC), Metastatic Castration Sensitive Prostate Cancer (MCSPC), Non-Metastatic Castration Resistant Prostate Cancer (nMCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT04839991
Phase:
Trial Summary: FIH, Phase 1, open-label, multi centre study of CB307, a trispecific Humabody® T-cell enhancer, in patients with advanced and/or metastatic PSMA+ solid tumours to assess safety and tolerability to de – clinicaltrials.gov for more information and location
Clinicaltrials.gov
Trial Sponsor(s): Crescendo Biologics Ltd.
Acronym: POTENTIA

Pin It on Pinterest